MicroRNA Profiles in Triple Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Triple negative breast cancer (TNBC) is an aggressive disease with higher proportion of Blacks affected and in younger age groups. There is no targeted therapy unlike other types of breast cancer such as hormone positive and Human Epidermal Growth factor 2 (HER2) positive subtypes. Chemotherapy is therefore the main choice of systemic treatment with rapid development of resistance in most cases. At present, there is no blood test to monitor treatment response and disease relapse. This one-stage phase II study with a single arm design will determine the response rate of standard chemotherapy using Epirubicin (60mg/m2), Cyclophosphamide (600mg/m2) , Paclitaxel (120mg/m2) and Carboplatin (6AUC) in TNBC patients. We will measure the blood level of microRNA molecules and circulating tumor DNA during and after treatment to test if changes can be used to indicate drug failure in these patients. Disease status and tumor response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines while toxicity will be assessed using CTCAE v5). The trial will be conducted as per the International Council on Harmonisation Good Clinical Practice (ICH GCP) Guidelines E6 (R1) and other applicable guidelines
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety w wieku 18-70 lat
- •Dostępny do biopsji guz piersi (≥2 cm)
- •Potwierdzony rak piersi typu potrójnie ujemnego
- •Stadium kliniczne IIA-IIIC
- •Brak wcześniejszej chemioterapii tego nowotworu
- •Dobry stan sprawności (ECOG 0-1)
- •Zgoda na stosowanie antykoncepcji hormonalnej przez 2 lata
- •Prawidłowe wyniki badań krwi, wątroby i nerek
- •Prawidłowa czynność serca
✗ Disqualifies
- •Ciąża lub karmienie piersią, brak skutecznej antykoncepcji
- •Przerzuty odległe (mózg lub narządy wewnętrzne)
- •Poważne, niekontrolowane zakażenie
- •Leczenie innego nowotworu w ciągu ostatnich 5 lat (z wyjątkami)
- •Udział w innym badaniu leku eksperymentalnego w ciągu ostatnich 4 tygodni
- •Inne poważne, niekontrolowane choroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- May 7, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (4)
Obafemi Awolowo University Teaching Hospital
Ile-Ife, Nigeria
University College Hospital
Ibadan, Nigeria
Lagos State University Teaching Hospital
Lagos, Nigeria
Lagos University Teaching Hospital
Lagos, Nigeria
Trial contact
Tonyin Aniagwu
Abiodun Oni
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.